A glimpse into the future: Integrating artificial intelligence for precision HER2‐positive breast cancer management
Abstract Breast cancer (BC), specifically HER2‐positives subtype, has a poor prognosis. Nevertheless, the development of anti‐HER2 therapy yielded satisfactory outcomes. Therefore, evaluating patient HER2 status and ascertaining responsiveness to anti‐HER2 therapy is crucial. The advent of deep lear...
Saved in:
Main Authors: | Xinpei Deng, Yixuan Yan, Zekai Zhan, Jindong Xie, Hailin Tang, Yutian Zou, Jian Tu, Peng Liu |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-09-01
|
Series: | iMetaOmics |
Subjects: | |
Online Access: | https://doi.org/10.1002/imo2.19 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Ultrasound Radiogenomics-based Prediction Models for Gene Mutation Status in Breast Cancer
by: Zhai Yue, Tan Dianhuan, Lin Xiaona, Lv Heng, Chen Yan, Li Yongbin, Luo Haiyu, Dan Qing, Zhao Chenyang, Xiang Hongjin, Zheng Tingting, Sun Desheng
Published: (2025-03-01) -
Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01) -
Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01) -
Nomograms for predicting recurrence of HER2‐positive breast cancer with different HR status based on ultrasound and clinicopathological characteristics
by: Xudong Zhang, et al.
Published: (2024-09-01) -
Trends in breast cancer among elderly women: Development in estrogen and HER2 subtypes in the last ten years
by: Frederik K. Palshof, et al.
Published: (2025-02-01)